Levaquin

NURS 2516 Clinical Medications Worksheets (You will need to make additional copies of these forms) Generic Name Trade Name lomefloxacin Levaquin

Peak End of infusion

Onset rapid

Classification Anti-infectives

Dose 750 g/150mL D5W Dose Range:

Duration 24 hrs

Mechanism of action and indications (Why med ordered) Inhibit bacterial DNA synthesis by inhibiting DNA gyrase. Acute diverticulitis.

Route IVPB

Time/frequency: Q 24 hrs Rate of Administration (IV): Infuse over 90 min.

For IV meds Compatibility with IV drips and /or solutions: Nursing Implications (what to focus on) Contraindications/warnings/interactions Hypersensitivity, notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional, history of QTc prolongation or proarrhythmic conditions such as recent hypokalemia, significant bradycardia, or recent myocardial ischemia. Patients with this history should not receive fluoroquinolones Common side effects Dizziness, drowsiness, headache, insomnia, seizures, pseudomembranous colitis, abdominal pain, diarrhea, nausea, anaphylaxis, Ste

Interactions with other patient drugs, OTC or herbal medicines (ask patient specifically) None Known

Lab value alterations caused by medicine Fluoroquinolones may cause ↑ serum AST, ALT, LDH, bilirubin, and alkaline phosphatase, May also cause ↓ WBC; ↑ or ↓ serum glucose; and glucosuria, hematuria, proteinuria, and albuminuria, Be sure to teach the patient the following about this medication Risk for infection, Encourage patient to maintain a fluid intake of at least 1500-2000 ml/day to prevent crystalluria, Advise patient to

Nursing Process- Assessment (Pre-administration assessment) Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC; urinalysis; frequency and urgency of urination; cloudy or foul-smelling urine) prior to and during therapy, Obtain specimens for culture and sensitivity before initiating therapy. First dose may be given before receiving results. To prevent development of resistant bacteria, therapy should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria,

notify health care professional of any personal or family history of QTc prolongation or proarrhythmic conditions such as recent hypokalemia, significant bradycardia, or recent myocardial ischemia. Patients with this history should not receive fluoroquinolones, Advise patient to report signs of superinfection (furry overgrowth on the tongue, vaginal itching or discharge, loose or foul-smelling stools), Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional, Instruct patient to notify health care professional immediately if rash or tendon pain or inflammation occur. Therapy should be discontinued. Assessment Evaluation Why would you hold or not give Check after giving this med? Resolution of the signs and Observe for signs and symptoms symptoms of infection. Time for of anaphylaxis (rash, pruritus, complete resolution depends on laryngeal edema, wheezing). organism and site of infection Discontinue drug and notify physician or other health care professional immediately if these problems occur. Keep epinephrine, an antihistamine, and resuscitation equipment close by in case of an anaphylactic reaction. Rash or tendon pain or inflammation occur.